Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Atai Beckley Inc.NASDAQ: ATAI

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $28.07M rose 154.5% year over year, ahead of the +47.5% change in trailing-twelve-month research & development. Sequentially, it rose 61.2% from the prior quarter. Over 3 fiscal years it compounded at -10.6% a year.

Context

  • Research & development amounted to 1297.7% of revenue in FY2025, down 16553.6 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +154.5% holds above the trailing-twelve-month pace of +47.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$28.07M+61.2% QoQ
Last fiscal yearDec 2025
$53.06M-3.5% YoY
LTMJun 2026
$79.04M+47.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+154.5%——
1 year-3.5%——
3-year CAGR-10.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
53.06M USD
Year-over-year change
-3.5%
4-year CAGR
+2.6%

Research & Development vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +47.5% is the 2nd highest of 11, against a peer median of +4.9%.
  • Research & development amounts to 1767.0% of revenue for ATAI, versus a peer median of 1577.4%.
ATAI Competitors
Research & Development for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLAYRelay Therapeutics, Inc.LTM Jun 2026$270.72M USD-4.1%+2.0%2615.7%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M USD+3.7%+29.7%117.9%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$175.6M USD+66.9%+70.5%9222.6%
SANASana Biotechnology, Inc.LTM Mar 2026$146.28M USD-4.6%-13.1%—
NKTRNektar TherapeuticsLTM Jun 2026$131.77M USD+6.1%-18.7%241.4%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$116.62M USD-0.1%+21.2%—
INBXInhibrx Biosciences, Inc.LTM Mar 2026$100.84M USD-42.7%+0.9%7756.8%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$100.83M USD+9.7%-1.1%—
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$98.95M USD+16.0%+40.4%—
ATAIAtai Beckley Inc.LTM Jun 2026$79.04M USD+47.5%-10.6%1767.0%
Peer median (excluding ATAI) —+4.9%+10.9%1577.4%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.38M233K314K308K4.09M
Cost of Revenue47K168K319K473K1.01M
Gross Profit20.33M65K(5K)(165K)3.08M
Gross Margin99.8%27.9%-1.6%-53.6%75.3%
Research & Development47.91M74.15M61.88M54.98M53.06M
Selling, General & Admin92.75M70.35M63.58M47.54M49.78M
Operating Expenses140.65M144.5M125.47M102.53M102.84M
Depreciation & Amortization47K168K319K473K1.01M
EBITDA(178.19M)(150.1M)(39.9M)(147.33M)(657.68M)
EBITDA Margin-874.5%-64419.3%-12708.3%-47835.4%-16084.0%
Operating Income(120.33M)(144.43M)(125.47M)(102.69M)(99.76M)
Operating Margin-590.5%-61987.1%-39958.9%-33341.2%-2439.7%
Interest Income205K548K1.85M778K1.48M
Interest Expense0923K2.66M3.12M1.16M
Other Income / Expenses(57.91M)(6.76M)82.59M(48.24M)(560.09M)
Income Before Tax(178.23M)(151.19M)(42.88M)(150.93M)(659.85M)
Pre-Tax Margin-874.7%-64887.6%-13655.7%-49003.2%-16137.2%
Income Tax Expense(3.99M)6.23M1.02M(881K)298K
Net Income(167.81M)(152.39M)(40.22M)(149.27M)(660.05M)
Net Margin-823.6%-65401.3%-12810.2%-48464.0%-16142.0%
EPS (Basic)(1.04)(0.98)(0.25)(0.93)(2.91)
EPS (Diluted)(1.04)(0.98)(0.25)(0.93)(2.91)
Weighted Avg Shares160.68M155.72M158.83M160.16M226.53M
Weighted Avg Shares (Diluted)160.68M155.72M158.83M160.16M226.53M

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.